Valerie Arboleda Uses Big Data to Unravel the Biology of a Rare Disease

The UCLA geneticist examines how defects in a histone protein lead to symptoms throughout the body.

Written byShawna Williams
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

© JOHN DAVIS PHOTOGRAPHYValerie Arboleda traces her love of research back to time spent in a lab as an undergraduate at Columbia University. “I think I was a little bit lucky, in that early on there were a couple of fun experiments that just worked,” she says. While working on a project examining cerebral ischemia, she was able to use qPCR to confirm that microRNAs had been transfected into cultured mouse neuronal cells and successfully knocked down a targeted gene. This motivated her to further investigate the biology behind this experiment, Arboleda recalls. “I kind of got hooked after that.”

At the time, however, Arboleda wasn’t convinced a career in research was practical, and after graduation, she opted to study medicine at the University of California, Los Angeles (UCLA). But her love of the lab lingered, and between her second and third years of med school, she did a full-time research training fellowship in the lab of geneticist Eric Vilain, where she ended up staying on after her year was up, eventually earning an MD/PhD. Vilain had been instrumental in describing a rare genetic disorder called IMAGe (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) syndrome in the late 1990s, when he was a resident. For more than a decade, “there had been numerous attempts by other groups [to identify the gene responsible] . . . and no one ever found it,” Vilain says. But Arboleda was able to track it down: using next-generation sequencing to compare the genomes of IMAGe patients with each other and with unaffected family members, she pinpointed variations in a specific stretch of a gene called CDKN1C.1

After earning her degrees, Arboleda started a UCLA residency in pathology that included a substantial research component. “She really was very engaged in her rotations, both intellectually and from the scientific curiosity perspective,” recalls Omai Garner, a pathologist with whom Arboleda worked regularly during her residency. Together with Garner, Arboleda spearheaded a study examining the types and quality of test results in the UCLA system that ended up in patients’ electronic medical records, drawing on statistical tools she’d used in earlier genomics work to crunch the numbers.2 “For somebody to take the initiative and to move [this kind of project] forward all the way through publication during their residency is very impressive,” Garner says.

During her transition from medical school to residency, Arboleda also worked ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile

Published In

May 2018

Rare Diseases

The realities of studying uncommon conditions

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies